Extreme hyperbilirubinemia can cause bilirubin neurotoxicity. Infants with glucose-6-phosphate dehydrogenase (G6PD) deficiency can develop hemolysis and thus are at high risk. We evaluated a device that quantitatively measures G6PD activity kinetically using digital microfluidics (DMF).
Intra- and inter-instrument and -day imprecision (CVs) were first assessed. G6PD activity in 86 samples was then measured and compared between DMF and 2 reference methods. Overall DMF reproducibility was 3.8% over 5 days by 2 operators on 2 instruments. Mean intra- and inter-instrument variabilities were 3.6% and 3.9%, respectively (n = 28), with a user variability of 4.3%. Mean G6PD activity was 6.40±4.62 and 6.37±4.62 U/g hemoglobin for DMF and Reference Methods 1 (n = 46) and 12.15±3.86 and 11.48±1.55 for DMF and 2 (n = 40), respectively, and strongly correlated (r = 0.95 and 0.95) with mean biases of +0.04±2.90 and +0.67±1.55 for methods 1 and 2, respectively. The novel device could be used for early newborn G6PD screening
Authors: Ronald J. Wong, Cynthia Montiel, Megana Kunda, David K. Stevenson, and Vinod K. Bhutani
Seminars in Perinatology. 2020, 0146-00050.
- Learn more about FINDER
- White Paper: Do More With Less: Approaches to Minimize Blood Loss in Critically Ill Newborns and Children
- Blog Post: 5 Things to Know about Testing with Digital Microfluidics
- RT-PCR within 17 minutes! Introducing FINDER 1.5 & FINDER SARS-CoV-2 Test